URGN
UroGen Pharma Ltd
43.30$
-1.6%
vs. previous close
Closing price · As of: Sep 18, 2026
Statements
Income Statement
UroGen Pharma Ltd (URGN) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 72 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 21 | 24 | 19 | 22 | 25 | 25 | 20 | 24 | 27 | 38 | 51 | 72 | 189 | |
| 2.4 | 2.3 | 1.7 | 2.2 | 2.5 | 2.5 | 2.3 | 3.6 | 3.3 | 3.3 | 4.1 | 6.6 | 17 | |
| 18 | 21 | 17 | 20 | 23 | 22 | 18 | 21 | 24 | 35 | 47 | 66 | 171 | |
| 10 | 11 | 15 | 15 | 11 | 15 | 20 | 19 | 14 | 14 | 16 | 17 | 61 | |
| 22 | 25 | 27 | 30 | 29 | 35 | 35 | 43 | 38 | 39 | 51 | 48 | 177 | |
| 32 | 36 | 43 | 45 | 40 | 50 | 55 | 62 | 52 | 54 | 67 | 66 | 238 | |
| -14 | -15 | -26 | -26 | -18 | -28 | -37 | -41 | -27 | -19 | -20 | 0.1 | -67 | |
| 3.8 | 3.6 | 2.4 | 3.5 | 2.7 | 3.9 | 4.1 | 8.8 | 8.0 | 13 | 8.7 | 4.9 | 35 | |
| -22 | -22 | -32 | -33 | -24 | -35 | -43 | -49 | -34 | -27 | -28 | -8.7 | -98 | |
| 0.0 | 3.9 | 0.1 | 0.0 | 0.1 | 2.6 | 0.4 | 1.0 | -1.1 | -0.3 | -4.8 | 5.6 | -0.5 | |
| -22 | -26 | -32 | -33 | -24 | -38 | -44 | -50 | -33 | -26 | -24 | -14 | -98 | |
| -12 | -7.4 | -24 | -30 | -15 | -26 | -39 | -49 | -26 | -22 | -19 | -3.8 | -71 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.